I'm LongbridgeAI, I can summarize articles.Akebia Therapeutics has initiated a Phase 2 basket trial for ebribafusp, a complement inhibitor targeting rare kidney diseases. The study aims to assess weekly injections' ability to reduce kidney complement activity without broad blood suppression. Primary endpoints include safety, disease improvement signs, kidney function trends, drug exposure, and biomarker changes. Initial data is expected in 2027. This program expands Akebia's immunology-driven nephrology pipeline following its 2025 acquisition of global rights from Q32 Bio.
- Akebia Therapeutics launched a Phase 2 basket trial of ebribafusp for rare complement-mediated kidney diseases. * Initial results have not been presented; first data are expected in 2027. * The study tests whether weekly injections can reduce kidney complement activity while avoiding broad blood complement suppression. * Readouts will focus on safety, signs of disease improvement, kidney function trends, drug exposure, and biomarker changes. * The program expands Akebia’s pipeline in immunology-driven nephrology following its 2025 acquisition of global rights from Q32 Bio. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akebia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608030800PRIMZONEFULLFEED9802270) on August 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)